Tumor News and Research

RSS

Beta-carotene safe to use during radiation therapy for prostate cancer

Despite past safety concerns, the antioxidant supplement beta-carotene, is safe to use during radiation therapy treatments for prostate cancer and does not increase the risk of prostate cancer death or metastases, according to a study in the May issue of the International Journal of Radiation Oncology•Biology•Physics, the official scientific journal of the American Society for Radiation Oncology.

1 Jun 2012

N-of-One develops unique knowledge integration platform for oncologists

N-of-One, Inc., provider of Diagnostic Strategy Roadmaps and Treatment Strategy Roadmaps for personalized cancer care, announced today that the company has developed a unique knowledge integration platform to enable care providers and patients to make informed decisions about diagnostic and treatment strategy.

1 Jun 2012

ImmunoCellular to present new data from ICT-107 Phase I trial on GBM

ImmunoCellular Therapeutics, Ltd., announced today it will present new data from the previously completed Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.

1 Jun 2012

Functional disability impacts educational attainment in children with JIA

As children with juvenile idiopathic arthritis (JIA) grow into adulthood, disability due to disease may adversely affect their ability to achieve educational success. Findings published in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), suggest that functional disability impacts educational attainment, which is key to successful employment in adulthood.

1 Jun 2012

Kindstar, Insight Genetics collaborate to improve cancer care in China

Molecular diagnostics company Insight Genetics and Kindstar Globalgene Technology, Inc., China's leading diagnostics company, today announced that the companies are partnering to enhance cancer care in the People's Republic of China and surrounding regions.

1 Jun 2012

NCI, Tau Therapeutics open enrollment in mibefradil Phase Ib glioma trial

Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that it has opened enrollment for a Phase Ib clinical trial with the National Cancer Institute's Adult Brain Tumor Consortium (ABTC) using the company's first product candidate mibefradil.

1 Jun 2012

Oncothyreon commences PX-866 and vemurafenib Phase 1/2 combination trial for melanoma

Oncothyreon Inc. today announced the initiation of a Phase 1/2 trial of PX-866 in combination with vemurafenib.

1 Jun 2012

Thrombosis biomarker levels differ according to thrombolysis strategy

An early invasive strategy following thrombolysis for ST-segment-elevation myocardial infarction is associated with significant changes in the levels of inflammatory and thrombotic biomarkers, a substudy of the Norwegian study on district treatment of STEMI shows.

31 May 2012

Juvenile Arthritis patients may have difficulties achieving educational success

31 May 2012

Taiho to initiate TAS-102 Phase III trial in colorectal cancer

Taiho Pharmaceutical Co., Ltd. announced on May 31 that a global Phase III clinical trial (RECOURSE) for the novel combination antimetabolite TAS-102 will start in June this year.

31 May 2012

UCLA research projects aim to improve lives of children with serious illnesses

New hope for deadly pediatric brain tumors; opening the door to improved diagnosis and treatment of epilepsy in children; and advanced genetic testing to better understand the causes of autism and cancer in kids. These research projects are currently underway at Mattel Children's Hospital UCLA under the umbrella of the UCLA Children's Discovery and Innovation Institute (CDI), and aim to dramatically improve the lives of children with serious illnesses.

31 May 2012

Data from Response Genetics' tests against cancer to be presented at ASCO 2012

Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced today four presentations to be held during the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 1 to June 5, 2012. Study results are based on the company's proprietary technology and approach.

31 May 2012

Foundation Medicine introduces first pan-cancer genomic profile

Foundation Medicine announced today the commercial launch of FoundationOne, the first pan-cancer, fully informative genomic profile designed to help oncologists expand their patients' treatment options.

31 May 2012

GE to provide attendees with overview of new oncology solutions at ASCO annual meeting

GE Healthcare, is working to help physicians potentially improve patient care throughout the breast cancer journey through one of the most comprehensive portfolios of technologies in the industry available today.

31 May 2012

Exelixis commences cabozantinib phase 3 pivotal trial in mCRPC

Exelixis, Inc. today announced the initiation of COMET-1, a phase 3 pivotal trial of cabozantinib in men with metastatic castration-resistant prostate cancer.

31 May 2012

Gender link discovered for colorectal cancer

Researchers have identified three new colorectal cancer risk loci, including one on the X-chromosome, bringing the total number of independent loci associated with the disease to 20.

30 May 2012

Pituitary tumors may lead to glaucomatous changes

Certain tumors of the pituitary gland are associated with glaucomatous abnormalities of the optic nerve head, such as enlarged beta zone, an international research team reports.

30 May 2012

CytRx INNO-206 doxorubicin conjugate shows anti-multiple myeloma effects

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that in animal and in vitro studies, its tumor-targeting doxorubicin conjugate INNO-206 showed anti-multiple myeloma effects and enhanced the anti-tumor effects of bortezomib, which is approved for the treatment of relapsed multiple myeloma.

30 May 2012

Nature Genetics publishes results from whole genome-wide study of recurrent HBV integration in HCC

The Asian Cancer Research Group (ACRG)—an independent, not-for-profit company established by Eli Lilly and Company, Merck (known as MSD outside the United States and Canada) and Pfizer Inc.—in collaboration with BGI—the world's largest genomics organization—today announced the publication of results from a whole genome-wide study of recurrent hepatitis B virus (HBV) integration in hepatocellular carcinoma (HCC) in Nature Genetics.

30 May 2012

ASCs promising source of cells for use in plastic surgery and regenerative medicine

Adipose stem cells (ASCs)—stem cells derived from fat—are a promising source of cells for use in plastic surgery and regenerative medicine, according to a special review in the June issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.

30 May 2012